TULIP 2: Efficacy and Safety of Anifrolumab in Patients

Update: 2019-12-23

Description

TULIP 2: Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial.

In this second phase 3 trial, the primary endpoint, BICLA, was achieved, and anifrolumab was superior to placebo for multiple secondary efficacy endpoints, including SRI(4), skin disease, and oral corticosteroid tapering.

Comments

In Channel

Use of imaging in large vessel vasculitis: EULAR 2023 update

2024-06-2131:43

Managing Systemic Lupus Erythematosus: the latest EULAR recommendations

2024-04-2221:25

A non-pharma approach in systemic lupus erythematosus and systemic sclerosis

2023-10-3018:55

Innate Lymphoid Cells link TGFb and fibrotic pathways in systemic sclerosis skin

2022-02-0721:41

Immunogenicity of anti-SARS-CoV-2 mRNA vaccines in patients with rheumatic diseases

2021-07-2920:37

The EULAR COVID-19 database and its insights into risk factors

2021-03-1825:43

Predictors of disease worsening in systemic sclerosis

2020-09-1511:34

Treating Cytokine Storm Syndrome in COVID-19 patients with glucocorticoids and tocilizumab

2020-08-0623:52

The dose dependent effect of statins on osteoporosis

2020-04-2212:06

A prediction score for individuals at risk to develop rheumatoid arthritis

2020-03-2512:06

Prediction of radiographic progression using synovitis characteristics

2020-03-0610:15

Six-week treatment with low-dose prednisolone in patients with painful hand osteoarthritis

2020-02-1803:08

Highlights from ACR: guselkumab, ixekizumab and secukinumab in SpA

2020-01-2314:56

TULIP 2: Efficacy and Safety of Anifrolumab in Patients

2019-12-2303:52

TULIP 1 - highlights from the ACR meeting

2019-12-1004:51

Capture Hi-C reveals novel drug targets in rheumatic diseases

2019-08-2214:03

EULAR recommendations for the management of systemic lupus erythematosus

2019-07-1210:05

Musculoskeletal diseases on the rise worldwide and affecting developed countries the most

2019-06-0313:18

Three tips to get your manuscript published by ARD

2018-08-2904:40

Early inflammatory arthritis outcomes: what changed in the new millennium?

2018-07-1009:58

00:00

1.0x

TULIP 2: Efficacy and Safety of Anifrolumab in Patients

#box-pro-ellipsis-176281741570495{-webkit-line-clamp:2;}TULIP 2: Efficacy and Safety of Anifrolumab in Patients

TULIP 2: Efficacy and Safety of Anifrolumab in Patients

BMJ Group

TULIP 2: Efficacy and Safety of Anifrolumab in Patients